NeuroSearch to cut workforce by 20% as it focuses on Huntington's candidate
This article was originally published in Scrip
NeuroSearch, which recently published promising results of a meta-analysis from two previous trials corroborating the potential of its Huntexil (pridopidine) to treat Huntington's disease, is cutting around 20% of its workforce and setting up a new division to house all its ion channel drug discovery and existing partner alliances.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.